We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+7.89%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$154M
AUM Growth
-$1.62M
Cap. Flow
+$2.97M
Cap. Flow %
1.93%
Top 10 Hldgs %
69.15%
Holding
39
New
4
Increased
2
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
ELTX icon
Elicio Therapeutics
ELTX
+$4.89M
2
SAND
Sandstorm Gold
SAND
+$4.37M
3
NUVB icon
Nuvation Bio
NUVB
+$2.33M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$1.69M
5
APLT
Applied Therapeutics
APLT
+$1.18M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$11.5M
2
SILV
SilverCrest Metals Inc. Common Shares
SILV
+$546K
3
GRAL
GRAIL Inc
GRAL
+$1.78K
4
IRD
Opus Genetics
IRD
+$53

Sector Composition

Rank Sector Weight
1 Healthcare 62.32%
2 Materials 25.02%
3 Industrials 1.61%
4 Consumer Staples 1.49%
5 Financials 1.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALDX icon
1
Aldeyra Therapeutics
ALDX
$91.7M
$31.5M 20.48%
5,475,516
– –
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$20M 12.99%
830,879
+70,457
+9% +$1.69M
ENTX icon
3
Entera Bio
ENTX
$101M
$10M 6.5%
5,881,879
– –
GLD icon
4
SPDR Gold Trust
GLD
$131B
$9.22M 6%
32,000
– –
MGTX icon
5
MeiraGTx Holdings
MGTX
$1.09B
$8.47M 5.51%
1,250,000
– –
AEM icon
6
Agnico Eagle Mines
AEM
$72.6B
$6.02M 3.91%
55,500
– –
ALT icon
7
Altimmune
ALT
$539M
$5.61M 3.65%
1,121,524
– –
KGC icon
8
Kinross Gold
KGC
$28.5B
$5.55M 3.61%
440,000
– –
SAND
9
DELISTED
Sandstorm Gold
SAND
$5.29M 3.44%
+700,000
New +$4.37M
AVDL
10
DELISTED
Avadel Pharmaceuticals
AVDL
$4.7M 3.06%
600,000
– –
OCUL icon
11
Ocular Therapeutix
OCUL
$1.86B
$4.4M 2.86%
600,400
– –
FNV icon
12
Franco-Nevada
FNV
$41.4B
$3.94M 2.56%
25,000
– –
ELTX icon
13
Elicio Therapeutics
ELTX
$78.8M
$3.89M 2.53%
+630,915
New +$4.89M
APLT
14
DELISTED
Applied Therapeutics
APLT
$3.81M 2.48%
7,799,687
+2,000,000
+34% +$1.18M
EQX icon
15
Equinox Gold
EQX
$7.32B
$3.79M 2.47%
550,811
– –
SA
16
Seabridge Gold
SA
$2.8B
$3.7M 2.41%
317,003
– –
SKE
17
Skeena Resources
SKE
$3.36B
$3.18M 2.07%
315,400
– –
MAG
18
DELISTED
MAG Silver
MAG
$2.6M 1.69%
170,000
– –
SLV icon
19
iShares Silver Trust
SLV
$28.1B
$2.48M 1.61%
80,000
– –
NUVB icon
20
Nuvation Bio
NUVB
$2.24B
$1.8M 1.17%
+1,025,000
New +$2.33M
V icon
21
Visa
V
$677B
$1.7M 1.11%
4,850
– –
PM icon
22
Philip Morris
PM
$301B
$1.59M 1.03%
10,000
– –
BAH icon
23
Booz Allen Hamilton
BAH
$8.7B
$1.36M 0.88%
13,000
– –
RGLD icon
24
Royal Gold
RGLD
$17.1B
$1.23M 0.8%
7,550
– –
ITA icon
25
iShares US Aerospace & Defense ETF
ITA
$14.2B
$1.17M 0.76%
7,650
– –
1
2

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Knoll Capital Management held 39 positions worth $154M, down 1% from $155M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Knoll Capital Management's Q1 2025 filing shows 4 new, 2 increased, 1 reduced and 3 closed positions. Its largest new stake was Elicio Therapeutics: 630,915 shares worth $3.89M. The largest sale was Verona Pharma, an estimated $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 72% a quarter earlier, followed by Materials and Industrials.

  • Knoll Capital Management's largest Q1 2025 buy was Elicio Therapeutics: 630,915 shares worth $3.89M.
  • Knoll Capital Management added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2025, an estimated $1.69M increase.
  • Knoll Capital Management's biggest Q1 2025 reduction was Verona Pharma, cutting an estimated $11.5M.
  • Knoll Capital Management fully exited SilverCrest Metals Inc. Common Shares in Q1 2025, selling an estimated $546K.
  • Knoll Capital Management's ten largest holdings make up 69% of its $154M portfolio in Q1 2025.
  • Knoll Capital Management opened 4 new positions and closed 3 in Q1 2025.
  • Knoll Capital Management's portfolio value fell 1% quarter-over-quarter to $154M.

Based on Knoll Capital Management's 13F filing for Q1 2025, filed 15 May 2025.